Omniscient Closes Series C Funding Round

Omniscient (o8t) has raised $60 million in a Series C funding round to help broaden its U.S. market footprint. Among the company’s investors are Australian business leaders Will Vicars and Gina Rinehart.

The funding is the company’s most recent milestone, as it has gained U.S. Food and Drug Administration (FDA) clearance for two products to date. Omniscient will utilize the proceeds to expand its presence in the U.S. market—where more than 100 hospitals and clinics use the company’s artificial intelligence-enabled connectomic analysis platform, Quicktome—and to advance product development efforts targeting expanded indications.
 
“At Omniscient, we create AI-driven technologies that are transforming how we understand and care for the brain. Our innovations empower doctors, therapeutics developers, and brain tech pioneers to make advances in brain science and treatment,” Omniscient Co-Founder/Chief Data Scientist Dr. Stephane Doyen said.
 
Quicktome, the company’s flagship platform, uses artificial intelligence (AI) to automatically decode and map the brain’s networks—responsible for everything from motor to language to emotion—using just a straightforward MRI scan. Omniscient recently expanded its product offering to include the first FDA-cleared neurological planning and visualization tool using resting-state fMRI, opening up new horizons for Quicktome in areas such as stroke, disorders of consciousness, and oncology. Now, the company’s technology is poised to bring the benefits of connectomic analysis to clinicians and patients across the brain health spectrum, from neurosurgery and neurology to mental health and beyond.
 
“As enthralled as the world is right now by the generative AI boom, it’s easy to forget that the most important data set on the planet—and the most impactful realm to apply advanced AI—is the human brain,” Omniscient CEO Stephen Scheeler stated. “We are thrilled to continue to lead the connectomics AI revolution worldwide, thanks to the support of our far-sighted investors, the talents of our team, and the dedication of our customers, partners, and collaborators.”
 
Omniscient uses AI to decode the human brain—a field known as connectomics. The company is an artificial intelligence innovation hub that creates advanced technologies to conquer the problems and enhance the brain’s potential. Omniscient’s connectomics AI platform, Quicktome, provides critical insights informing prognosis and planning across neurologic conditions, from cranial surgery and neuro-oncology to stroke and beyond. Omniscient intends to help conquer conditions such as Alzheimer’s disease and depression through truly personalized brain medicine.